ROCKVILLE, Md., Jan. 6, 2025 /PRNewswire/ — Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, today announced that it has completed dose escalation enrollment stages for both its R-2487 and R-3750 clinical trials. Both studies…